Last reviewed · How we verify
Cilostazol Tablets
Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.
Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation. Used for Intermittent claudication due to peripheral arterial disease, Secondary prevention of ischemic stroke.
At a glance
| Generic name | Cilostazol Tablets |
|---|---|
| Also known as | Cilostazol-SR |
| Sponsor | Gyeongsang National University Hospital |
| Drug class | Phosphodiesterase-3 inhibitor |
| Target | PDE-3 (Phosphodiesterase-3) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
By blocking PDE-3 in vascular smooth muscle and platelets, cilostazol elevates cyclic adenosine monophosphate (cAMP), which leads to vasodilation of blood vessels and reduced platelet clumping. This dual action improves blood flow and reduces thrombotic events, making it effective for peripheral arterial disease and stroke prevention.
Approved indications
- Intermittent claudication due to peripheral arterial disease
- Secondary prevention of ischemic stroke
Common side effects
- Headache
- Diarrhea
- Palpitations
- Dizziness
- Tachycardia
Key clinical trials
- Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial (PHASE2)
- CiLostAzol for pReventIon of Recurrent sTroke in Africa (PHASE3)
- Cilostazol for Prevention of Recurrent Stroke Trial (PHASE3)
- Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage (PHASE3)
- Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA (PHASE3)
- The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis (PHASE1, PHASE2)
- Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease (PHASE1, PHASE2)
- The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cilostazol Tablets CI brief — competitive landscape report
- Cilostazol Tablets updates RSS · CI watch RSS
- Gyeongsang National University Hospital portfolio CI